Phase I/II Study of Dasatinib and Osimertinib (AZD9291) in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations Read more
Molecular profiling in patients with advanced lung or thymic cancer previously treated with immune checkpoint inhibitor therapy. Read more
A Phase 2 Precision Oncology Study of Biomarker-Directed, Pembrolizumab- (MK-3475, SCH 900475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (KEYNOTE-495; KeyImPaCT) Read more
A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study Of Pembrolizumab (MK-3475) In Combination With Concurrent Chemoradiation Therapy Followed By Pembrolizumab With Or Without Olaparib (MK-7339), Compared To Concurrent Chemoradiation Therapy Alone In Participants With Actively Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) Read more
A Phase 2 Trial of MRTX849 in Combination with Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation Read more
A Phase 1b/2 Clinical Study Of Intratumoral Administration Of V937 In Combination With Pembrolizumab (MK-3475) In Participants With Advanced/Metastatic Solid Tumors Read more
A Phase 1/2, Open-Label, Dose-Escalation, Safety And Tolerability Study Of NC318 In Subjects With Advanced Or Metastatic Solid Tumors Read more
A Phase 1/2, Open-Label, Dose-Escalation, Safety And Tolerability Study Of NC410 In Subjects With Advanced Or Metastatic Solid Tumors Read more
A Phase 1, Open-Label, Multi-Center, Dose-Finding, Pharmacokinetic, Safety And Tolerability Study Of Pf-07265807 In Participants With Selected Advanced Or Metastatic Solid Tumor Malignancies Read more
